Bioxytran Inc.

Bioxytran ($BIXT) is pleased to announce the successful completion of its second randomized double-blind, placebo-controlled clinical trial for its leading broad-spectrum antiviral drug candidate, ProLectin-M. Data from the trial is expected to inform both the CDSCO for a phase 3 trial design and will also be submitted to the FDA pursuant to their request.

READ FULL PRESS RELEASE:
https://tinyurl.com/bdw7nac8

Bioxytran CCO Mike Sheikh will talk about the Medical Breakthrough in & his LinkedIn article on in his interview on Thursday, October 31, 2024 from 1:10 - 1:40 PM Eastern.

Click to register: https://tinyurl.com/4rhsndbm